With a new year comes new expectations. 24/7 Wall St. has generated a bullish and bearish scenario for 2014 in each stock of the Dow, including Pfizer and rival Merck & Co.
courtesy of VerizonThe short interest data for the end of November is out, and the results are somewhat surprising when it comes to the top high-yield safe dividends out there. Some of the…
ThinkstockThere is a trend at the end of each year followed by many income investors. This is the Dogs of the Dow, which is simply made up of the 10 Dow Jones…
ThinkstockInvestors love dividends, particularly safe and dependable dividends that rise through time. The S&P 500 Index currently has the most companies paying dividends in nearly two decades. The year 2013 has seen…
ThinkstockThe market for pharmaceuticals and biotech drugs just keeps growing. The so-called patent cliff may be affecting Big Pharma companies locally, but a new report from IMS Health shows that the total…
ThinkstockSkin cancer treatments remain elusive. While some drugs are on the market for advanced-stage treatment, the most common and longest method of initial treatment still involves the doctor taking the scalpel and…
Jon C. Ogg While the past two years were all about getting the house back in order, the UBS equity strategy team thinks 2014 is all about earnings growth. That should be sweet music to…
We have now seen the short interest reports from the October 31 settlement date and have compared them to the October 15 settlement date. This is important because it reflects the opinions…
ThinkstockThe unemployment situation in the United States looked relatively good through the first half of the year. The jobless rate dropped to 7.3% in October from 7.9%% at the beginning of the…
ThinkstockOctober’s jobs report showed a gain of 204,000 people to nonfarm payrolls. That is a pace of 1.5 million job additions for 2013. Many earlier months have been better. The Bureau of Labor…
Douglas A. McIntyre Jon OggInvestors are having to deal with seeing stocks hit new highs almost daily now. With a temporary deal in Washington, D.C., and with earnings coming on strong, investors are caught trying…
The drug patent cliff for Big Pharma is coming with some continued consequences, and two drug giants with earnings this week are Dow Jones Industrial Average components. Merck & Co. (NYSE: MRK) reported…
ThinkstockDrug giant Merck & Co. Inc. (NYSE: MRK) reported third-quarter 2013 results before markets opened Monday morning. The company posted adjusted diluted earnings per share (EPS) of $0.92 and revenues of $11.03…
Paul Ausick courtesy of Verizon WirelessMergers and acquisitions (M&A) sometimes can be an excellent measure of the economy’s financial health. However, since there is a great deal of evidence that most M&A results are…
Jon OggEarnings season is in full swing and this coming week will bring many key earnings reports. This will also be the last week of major on-calendar earnings for the third quarter,…
